ARGX vs MEDP
argenx SE vs Medpace — AI-powered side-by-side comparison
| Metric | ARGX | MEDP |
|---|
| AI Score |
66
|
64
|
| Price |
$876.01
|
$596.78
|
| P/E Ratio |
31.23×
|
34.82×
|
| ROE |
17.6%
|
98.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
28.8%
|
| Debt / Equity |
0.01×
|
0.28×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
72.1
|
| Beta |
-0.022
|
1.151
|
| Expected Upside |
+1.8%
|
+3.0%
|
AI Committee View
Current Innellis committee reasoning for ARGX versus MEDP.
ARGX leads by 2 points.
ARGX scores 66/100 (Buy) versus MEDP at 64/100 (Buy).
ARGX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 34.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.2 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical